- Previous Close
6.580 - Open
6.700 - Bid 6.490 x --
- Ask 6.510 x --
- Day's Range
6.410 - 6.700 - 52 Week Range
4.940 - 7.700 - Volume
3,507,000 - Avg. Volume
5,616,533 - Market Cap (intraday)
16.289B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-0.450 - Earnings Date Mar 19, 2025 - Mar 24, 2025
- Forward Dividend & Yield 0.18 (2.67%)
- Ex-Dividend Date Jun 18, 2024
- 1y Target Est
8.98
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.
www.simcere.com6,412
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 2096.HK
View MorePerformance Overview: 2096.HK
Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2096.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2096.HK
View MoreValuation Measures
Market Cap
16.34B
Enterprise Value
14.35B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.52
Price/Book (mrq)
2.23
Enterprise Value/Revenue
2.13
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-17.39%
Return on Assets (ttm)
4.79%
Return on Equity (ttm)
-13.81%
Revenue (ttm)
6.34B
Net Income Avi to Common (ttm)
-1.1B
Diluted EPS (ttm)
-0.450
Balance Sheet and Cash Flow
Total Cash (mrq)
3.06B
Total Debt/Equity (mrq)
17.11%
Levered Free Cash Flow (ttm)
74.62M